Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axitinib - Pfizer

Next Previous
Drug Profile

Axitinib - Pfizer

Alternative Names: AG-013736; AG-13,736; Inlyta

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Tumores Neuroendocrinos; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme; Netherlands Cancer Institute; Pfizer; Royal Marsden Hospital; SCRI Development Innovations; SFJ Pharmaceuticals; Sheffield Teaching Hospitals NHS Foundation Trust; University of Cincinnati; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Benzamides; Eye disorder therapies; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II/III Neuroendocrine tumours
  • Phase II Carcinoid tumour; Colorectal cancer; Endometrial cancer; Glioblastoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Soft tissue sarcoma; Urogenital cancer
  • No development reported Solid tumours
  • Discontinued Breast cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 05 Jun 2023 Pfizer in collaboration with MD Anderson cancer center completes a phase-II clinical trials in Renal cell carcinoma (Neoadjuvant therapy, Late-stage disease) in USA (PO) (NCT01263769)
  • 02 Jun 2023 Efficacy data from phase II trial in Endometrial cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 02 Jun 2023 Efficacy and adverse events data from the phase III KEYNOTE-426 trial in Renal cell carcinoma presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top